Frank Morris, MD
Interventional Cardiology · Towson, MDNPI 1891789988
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,738 and has fallen 66.6% since, to $581 in 2024. That places this record below the midpoint for interventional cardiology clinicians in MD, where the typical reported total is $7,370.
Across 207 payments — averaging $27.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$776
- E.r. Squibb & Sons, L.L.C.$747
- Medtronic$614
- Novartis$524
- Abbott$461
- Edwards Lifesciences$308
- plus $2K from 22 others
Across 1 payment — averaging $3000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3K
What the payments were for
- Food & beverage$5,752100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 34 | $776 |
| E.r. Squibb & Sons, L.L.C. | 30 | $747 |
| Medtronic | 5 | $614 |
| Novartis | 32 | $524 |
| Abbott | 3 | $461 |
| Edwards Lifesciences | 3 | $308 |
| Boston Scientific | 3 | $288 |
| Amgen | 12 | $282 |
| Pfizer | 9 | $268 |
| Gilead | 23 | $222 |
| Scpharmaceuticals Inc. | 6 | $213 |
| AstraZeneca | 8 | $145 |
| Kowa Pharmaceuticals America, Inc. | 6 | $136 |
| Abiomed | 1 | $114 |
| Merck | 7 | $110 |
| Novo Nordisk | 5 | $99 |
| Atricure, Inc. | 2 | $94 |
| Bayer | 3 | $70 |
| Johnson & Johnson | 2 | $49 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Irhythm Technologies, Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Akcea Therapeutics, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONYX FRONTIER$368
- ELIQUIS$276
- AVEIR$185
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$177
- Resolute$157
- WATCHMAN Access System$142
- GENERAL - STRUCTURAL HEART$121
- FUROSCIX$121
- Edwards SAPIEN 3 Transcatheter Heart Valve$121
- Impella$114
- JARDIANCE$108
- VYNDAQEL$107
How this compares
$5,766 in reported general payments places this provider in the 40th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 560 | $576,545 |
| XareltoRivaroxaban | 97 | $125,407 |
| JardianceEmpagliflozin | 135 | $99,865 |
| EntrestoSacubitril/Valsartan | 62 | $78,137 |
| Repatha SureclickEvolocumab | 35 | $43,668 |
| FarxigaDapagliflozin Propanediol | 21 | $12,522 |
| Praluent PenAlirocumab | 24 | $12,352 |
| Metoprolol Succinate | 613 | $10,630 |
| Atorvastatin Calcium | 489 | $7,765 |
| Rosuvastatin Calcium | 253 | $5,464 |
| Flecainide Acetate | 95 | $4,935 |
| Amiodarone Hcl | 139 | $4,862 |
| Ranolazine ErRanolazine | 48 | $3,996 |
| Amlodipine Besylate | 441 | $3,555 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 66 | $2,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $268 | $576,545560 claims |
| Johnson & JohnsonXarelto | $49 | $125,40797 claims |
| Boehringer IngelheimJardiance | $776 | $99,865135 claims |
| NovartisEntresto | $524 | $78,13762 claims |
| AstraZenecaFarxiga | $145 | $12,52221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 71 interventional cardiology providers in Maryland.
Other interventional cardiology in Towson
- Syed ZaidiTowson$15K
- Michael DrossnerTowson$15K
- Vinay SatwahGreenbelt$679K
- Aloke FinnBaltimore$575K
- Michael ChenRockville$241K
- John WangBaltimore$138K
- Steven HearneSalisbury$100K
- Amir NajafiBel Air$82K
- Diljon ChahalBaltimore$78K
- Joseph CinderellaSalisbury$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.